SALARIUS PHARMACEUTICALS INC SLRX 深 滬
等待開盤 09-17 09:30:00 美东时间
5.69
+0.245
+4.50%
華盛通- 最 高5.90
- 今 開5.28
- 成交量 26.68万股
- 最 低 5.21
- 昨 收 5.445
- 總市值 289.96万
- 52周最高 108.00
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 4.50
- 委 比 52.89%
- 總股本 50.96万
- 歷史最高 44445.00
- 量 比 0.39
- 振 幅 12.67%
- 歷史最低 5.21
- 每 手 1
- 風險率 1.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Salarius Pharmaceuticals regains compliance with Nasdaq minimum bid price requirement
Salarius Pharmaceuticals (NASDAQ:SLRX) on Tuesday said it has received notification from Nasdaq that it has regained compliance with the Minimum Bid Price Requirement. As disclosed on August 27, Salar...
09-09 20:09
Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
Salarius Pharmaceuticals regained compliance with Nasdaq's Minimum Bid Price Requirement and must meet the Equity Standard Requirement by October 20, 2025. The company is under a one-year monitor. Salarius also announced a merger with Decoy Therapeutics to form a new company focused on peptide conjugate therapeutics targeting respiratory infectious diseases and GI oncology. Salarius' SP-3164 will be integrated into PROTACs. The combined company p...
09-09 12:00
Decoy Therapeutics Reports Financial Downturn Amid Funding Challenges
An announcement from Salarius Pharmaceuticals ( ($SLRX) ) is now available. Dec...
08-23 05:53
Salarius Pharmaceuticals Appoints New Acting CEO
Salarius Pharmaceuticals ( ($SLRX) ) just unveiled an announcement. On August 1...
08-18 20:59
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers IO Biotech (NASDAQ:IOBT) stock rose 52.5% to $2.76 during Monday's pre...
08-11 20:08
Why Celestica Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Shares of Celestica Inc. (NYSE:CLS) rose sharply in pre-market trading after th...
07-29 18:46
Salarius Pharmaceuticals Modifies Security Holders’ Rights
Salarius Pharmaceuticals ( ($SLRX) ) has provided an announcement. Salarius Pha...
07-22 10:02
Salarius Pharmaceuticals Granted Nasdaq Compliance Extension
Salarius Pharmaceuticals ( ($SLRX) ) has issued an announcement. On July 10, 20...
07-14 20:59
Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard
<p><strong>Salarius Pharmaceuticals</strong> (Nasdaq: SLRX) has been granted an additional extension until late July 2025 to regain compliance with Nasdaq's $2.5 million stockholders' equity requirement, and until early August 2025 to meet the $1.00 minimum bid price requirement for continued listing. Salarius is merging with Decoy Therapeutics, a biopharmaceutical company focused on peptide conjugate therapeutics, to form a new company named Dec...
07-14 12:30
Salarius Pharmaceuticals Announces Two Animal Studies Recently Published In Journals Demonstrating Role Of LSD1
Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) (Salarius or the Company) announces that two animal studies recently published in peer-reviewed journals provide additional insight into the role of inhibiting
07-09 20:31
